SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe and broadly accessible therapies.
Şu anda bir Faz 2 önemli denemesinde araştırılmakta olan CART-ddBCMA, Arcellx'in şirketin yeni sentetik bağlayıcısı D-Domain'i kullanan T-hücre tedavisidir. Kite ve Arcellx, CART-ddBCMA varlığını ABD'de ortaklaşa geliştirip ticarileştirecek ve Kite, ürünü ABD dışında ticarileştirecek
CAR T-Cell tedavisi belirli kan kanseri türleri için çığır açan tedaviler arasındadır. Devam eden 750'den fazla var klinik denemeler in Çin'de CAR T-Cell tedavisi şu anda. Kayıt yaptırmak isteyenler iletişime geçebilirler. YengeçFaks WhatsApp'ta hasta yardım hattı +91 96 1588 1588 veya adresine e-posta gönder info@cancerfax.com.
Arcellx Hakkında
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multipl miyelom (r/r MM) in a Phase 2 pivotal trial. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.
Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, through two programs: a Phase 1 study of ACLX-001 for r/r MM, initiated in the second quarter of 2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk miyelodisplastik sendrom, initiated in the fourth quarter of 2022.
Uçurtma Hakkında
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial supply, and commercial product manufacturing.
Gilead Bilimleri Hakkında
Gilead Sciences, Inc., tüm insanlar için daha sağlıklı bir dünya yaratma hedefiyle otuz yılı aşkın süredir tıpta atılımları takip eden ve başaran bir biyofarmasötik şirketidir. Şirket, HIV, viral hepatit ve kanser gibi yaşamı tehdit eden hastalıkları önlemek ve tedavi etmek için yenilikçi ilaçlar geliştirmeye kararlıdır. Gilead, merkezi Foster City, Kaliforniya'da olmak üzere dünya çapında 35'ten fazla ülkede faaliyet göstermektedir. Gilead Sciences, 2017 yılında Kite'ı satın aldı.
